Automated Drug Compounding Systems Market Report 2026

The automated drug compounding systems market size has grown rapidly in recent years. It will grow from $1.85 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing adoption of automated systems in hospital pharmacies, rising need to minimize medication errors, growing focus on sterile and accurate drug preparation, increasing workflow burden on pharmacy staff, and rising demand for time-saving compounding processes.

The automated drug compounding systems market size is expected to see rapid growth in the next few years. It will grow to $3.28 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to growing investment in healthcare automation, increasing integration of software and automation tools, rising need for standardization in drug compounding, growing focus on reducing contamination risks, increasing hospital spending on automation infrastructure, and rising need for operational efficiency in pharmacies. Major trends in the forecast period include advancement in robotic-assisted drug compounding technologies, innovation in software integration for pharmacy management, integration of AI for error reduction in compounding processes, advancement in real-time monitoring and quality control systems, and innovation in automated sterile compounding techniques.

The rising prevalence of chronic diseases is anticipated to drive the growth of the automated drug compounding systems market in the coming years. Chronic diseases are long-term health conditions that typically progress gradually, such as diabetes, heart disease, and arthritis, often necessitating ongoing medical care and lifestyle management to control symptoms and prevent complications. The increase in chronic diseases is largely attributed to unhealthy lifestyles, including poor diet, physical inactivity, and smoking, which elevate the risk of conditions like diabetes, heart disease, and obesity. Automated drug compounding systems support chronic disease management by accurately preparing personalized medications tailored to each patient’s requirements. They enhance treatment precision and consistency, reduce errors, and improve long-term therapeutic outcomes. For example, in June 2024, the National Health Service (UK) reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (elevated blood sugar levels not yet classified as diabetes) in 2023, representing an 18% increase from 3,065,825 cases in 2022. Thus, the growing prevalence of chronic diseases is fueling the demand for automated drug compounding systems.

The shortage of skilled pharmacy personnel is also expected to drive the growth of the automated drug compounding systems market. This shortage refers to the limited availability of trained pharmacists and technicians capable of safely preparing and dispensing medications in hospitals, clinics, and compounding pharmacies. The increasing gap in skilled pharmacy staff is attributed to rising patient volumes and the growing prevalence of chronic conditions that require precise pharmaceutical care. Automated drug compounding systems mitigate this challenge by enabling accurate, consistent, and efficient medication preparation with minimal human intervention, thereby reducing errors and alleviating the workload of pharmacy staff. For instance, in August 2024, the National Center for Health Workforce Studies (US) projected a shortage of 4,980 pharmacists over the next 15 years through 2036, while overall demand for pharmacists is expected to grow by 3% from 2022 to 2032, raising concerns amid declining application trends. Consequently, the shortage of skilled pharmacy personnel is propelling the growth of the automated drug compounding systems market.

Leading companies operating in the automated drug compounding systems market are focusing on developing advanced systems, such as total parenteral nutrition (TPN) automation systems, to improve accuracy, safety, and efficiency in preparing personalized intravenous formulations. A total parenteral nutrition (TPN) automation system refers to a compounding platform that not only automates the mixing and dispensing of total parenteral nutrition (TPN) solutions but also integrates prescription validation and workflow management tools to reduce human error and ensure sterile, high-quality preparation. For instance, in May 2025, MediServ Co. Ltd. launched the APEX TPN Compounding System in Riyadh, ushering in a new era of precision and automation for parenteral nutrition workflows. The system, showcased with its EasyComp integration software, enhances the total parenteral nutrition (TPN) process by linking validated prescriptions through to sterile, accurate compounding, streamlining pharmacy operations and reducing manual tasks.

Major companies operating in the automated drug compounding systems market are Becton Dickinson and Company, Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, ICU Medical Inc., Omnicell Inc., Eckert & Ziegler SE, Swisslog Healthcare AG, EQUASHIELD Medical Ltd., Trasis S.A., Loccioni Group S.p.A., ARxIUM Inc., Comecer S.p.A., Tema Sinergie S.p.A., Epic Medical Pte. Ltd., IBA Radiopharma Solutions S.A., Steriline S.r.l., Elysia-Raytest GmbH, Curifylabs OY, Kapsam Health Solutions Pvt. Ltd.

North America was the largest region in the automated drug compounding Systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated drug compounding systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automated drug compounding systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have affected the automated drug compounding systems market by increasing the cost of imported robotics, software, and specialized consumables, leading to higher production expenses. hospitals and compounding pharmacies in north america and europe are particularly impacted due to reliance on imported high-precision equipment. while tariffs have increased costs, they have also encouraged local manufacturing and innovation, creating opportunities for domestic suppliers to expand and optimize automation solutions.

Automated drug compounding systems are advanced technologies engineered to precisely prepare customized medications with minimal human involvement. They employ robotics, software, and controlled environments to maintain accuracy, sterility, and consistency in drug formulation. These systems help minimize errors, enhance safety, and optimize pharmacy operations.

The main product categories of automated drug compounding systems include robotic compounding systems, automated liquid compounding systems, tablet and capsule dispensers, injectable compounding robots, IV admixture systems, and oral liquid compounding systems. Robotic compounding systems are fully automated platforms designed to prepare sterile and non-sterile medications accurately while minimizing human error and hazardous exposure. Components include specialized equipment, software, consumables, and services. Technologies include robotic systems, semi-automated systems, gravimetric and volumetric dosing, and hybrid dosing systems. Key end users include hospitals, clinics, retail pharmacies, compounding pharmacies, and pharmaceutical manufacturers.

The automated drug compounding systems market consists of revenues earned by entities by providing services such as automated medication preparation, sterile drug compounding, accuracy verification, workflow optimization support, system maintenance, and software-based monitoring and control. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated drug compounding systems market also includes sales of robotic compounding units, automated liquid and powder compounding systems, software platforms for compounding accuracy, and related accessories and components. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.